{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T14:38:06Z","timestamp":1791297486505,"version":"4.1.0"},"reference-count":50,"publisher":"American Society of Hematology","issue":"14","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2012,10,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Inhibition of leukocyte adhesion to the vascular endothelium represents a novel and important approach for decreasing sickle cell disease (SCD) vaso-occlusion. Using a humanized SCD\u2013mouse-model of tumor necrosis factor-\u03b1\u2013induced acute vaso-occlusion, we herein present data demonstrating that short-term administration of either hydroxyurea or the phosphodiesterase 9 (PDE9) inhibitor, BAY73-6691, significantly altered leukocyte recruitment to the microvasculature. Notably, the administration of both agents led to marked improvements in leukocyte rolling and adhesion and decreased heterotypic red blood cell-leukocyte interactions, coupled with prolonged animal survival. Mechanistically, these rheologic benefits were associated with decreased endothelial adhesion molecule expression, as well as diminished leukocyte Mac-1-integrin activation and cyclic guanosine monophosphate (cGMP)\u2013signaling, leading to reduced leukocyte recruitment. Our findings indicate that hydroxyurea has immediate beneficial effects on the microvasculature in acute sickle-cell crises that are independent of the drug's fetal hemoglobin-elevating properties and probably involve the formation of intravascular nitric oxide. In addition, inhibition of PDE9, an enzyme highly expressed in hematopoietic cells, amplified the cGMP-elevating effects of hydroxyurea and may represent a promising and more tissue-specific adjuvant therapy for this disease.<\/jats:p>","DOI":"10.1182\/blood-2012-02-409524","type":"journal-article","created":{"date-parts":[[2012,7,26]],"date-time":"2012-07-26T03:12:51Z","timestamp":1343272371000},"page":"2879-2888","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":99,"title":["Hydroxyurea and a cGMP-amplifying agent have immediate benefits on acute vaso-occlusive events in sickle cell disease mice"],"prefix":"10.1182","volume":"120","author":[{"given":"Camila Bononi","family":"Almeida","sequence":"first","affiliation":[{"name":"Hematology and Hemotherapy Center, Instituto Nacional de Ci\u00eancia e Tecnologia do Sangue (INCTS), UNICAMP, Campinas, S\u00e3o Paulo, Brazil;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Scheiermann","sequence":"additional","affiliation":[{"name":"Ruth L. and David S. Gottesman Institute for Stem Cell and Regenerative Medicine Research, Albert Einstein College of Medicine, Bronx, NY; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung-Eun","family":"Jang","sequence":"additional","affiliation":[{"name":"Ruth L. and David S. Gottesman Institute for Stem Cell and Regenerative Medicine Research, Albert Einstein College of Medicine, Bronx, NY; and"},{"name":"Departments of Medicine and"},{"name":"Gene and Cell Medicine, Mount Sinai School of Medicine, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colette","family":"Prophete","sequence":"additional","affiliation":[{"name":"Ruth L. and David S. Gottesman Institute for Stem Cell and Regenerative Medicine Research, Albert Einstein College of Medicine, Bronx, NY; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando Ferreira","family":"Costa","sequence":"additional","affiliation":[{"name":"Hematology and Hemotherapy Center, Instituto Nacional de Ci\u00eancia e Tecnologia do Sangue (INCTS), UNICAMP, Campinas, S\u00e3o Paulo, Brazil;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Conran","sequence":"additional","affiliation":[{"name":"Hematology and Hemotherapy Center, Instituto Nacional de Ci\u00eancia e Tecnologia do Sangue (INCTS), UNICAMP, Campinas, S\u00e3o Paulo, Brazil;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul S.","family":"Frenette","sequence":"additional","affiliation":[{"name":"Ruth L. and David S. Gottesman Institute for Stem Cell and Regenerative Medicine Research, Albert Einstein College of Medicine, Bronx, NY; and"},{"name":"Departments of Medicine and"},{"name":"Gene and Cell Medicine, Mount Sinai School of Medicine, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"23","key":"2019111809163294100_B1","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1056\/NEJM199406093302303","article-title":"Mortality in sickle cell disease. Life expectancy and risk factors for early death.","volume":"330","author":"Platt","year":"1994","journal-title":"N Engl J Med"},{"issue":"9442","key":"2019111809163294100_B2","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1016\/S0140-6736(04)17192-4","article-title":"Sickle-cell disease.","volume":"364","author":"Stuart","year":"2004","journal-title":"Lancet"},{"issue":"18","key":"2019111809163294100_B3","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1056\/NEJM198005013021803","article-title":"Erythrocyte adherence to endothelium in sickle-cell anemia: a possible determinant of disease severity.","volume":"302","author":"Hebbel","year":"1980","journal-title":"N Engl J Med"},{"issue":"4","key":"2019111809163294100_B4","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1172\/JCI30920","article-title":"Sickle cell disease: old discoveries, new concepts, and future promise.","volume":"117","author":"Frenette","year":"2007","journal-title":"J Clin Invest"},{"issue":"5","key":"2019111809163294100_B5","doi-asserted-by":"crossref","first-page":"3047","DOI":"10.1073\/pnas.052522799","article-title":"Primary role for adherent leukocytes in sickle cell vascular occlusion: a new paradigm.","volume":"99","author":"Turhan","year":"2002","journal-title":"Proc Nat Acad Sci U S A"},{"issue":"10","key":"2019111809163294100_B6","doi-asserted-by":"crossref","first-page":"3953","DOI":"10.1182\/blood-2002-10-3313","article-title":"Transgenic sickle mice have vascular inflammation.","volume":"101","author":"Belcher","year":"2003","journal-title":"Blood"},{"issue":"11","key":"2019111809163294100_B7","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1016\/j.freeradbiomed.2007.08.014","article-title":"Redox-dependent impairment of vascular function in sickle cell disease.","volume":"43","author":"Aslan","year":"2007","journal-title":"Free Radic Biol Med"},{"issue":"6","key":"2019111809163294100_B8","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1182\/blood-2003-07-2209","article-title":"Intravenous immune globulin prevents venular vaso-occlusion in sickle cell mice by inhibiting leukocyte adhesion and the interactions between sickle erythrocytes and adherent leukocytes.","volume":"103","author":"Turhan","year":"2004","journal-title":"Blood"},{"issue":"4","key":"2019111809163294100_B9","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1038\/nm.1939","article-title":"Heterotypic interactions enabled by polarized neutrophil microdomains mediate thromboinflammatory injury.","volume":"15","author":"Hidalgo","year":"2009","journal-title":"Nat Med"},{"issue":"11","key":"2019111809163294100_B10","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.3324\/haematol.2010.026294","article-title":"Aggregation of mononuclear and red blood cells through \u03b14\u03b21-Lu\/BCAM interaction in sickle cell disease.","volume":"95","author":"Chaar","year":"2010","journal-title":"Haematologica"},{"issue":"10","key":"2019111809163294100_B11","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1182\/blood-2009-12-260513","article-title":"GMI-1070, a novel pan-selectin antagonist, reverses acute vascular occlusions in sickle cell mice.","volume":"116","author":"Chang","year":"2010","journal-title":"Blood"},{"issue":"12","key":"2019111809163294100_B12","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1038\/nm1202-799","article-title":"Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease.","volume":"8","author":"Reiter","year":"2002","journal-title":"Nat Med"},{"issue":"1","key":"2019111809163294100_B13","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.blre.2006.07.001","article-title":"Deconstructing sickle cell disease: reappraisal of the role of hemolysis in the development of clinical subphenotypes.","volume":"21","author":"Kato","year":"2007","journal-title":"Blood Rev"},{"issue":"6","key":"2019111809163294100_B14","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1111\/j.1365-2141.2008.07259.x","article-title":"Sodium nitrite promotes regional blood flow in patients with sickle cell disease: a phase I\/II study.","volume":"142","author":"Mack","year":"2008","journal-title":"Br J Haematol"},{"issue":"10","key":"2019111809163294100_B15","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1002\/ajh.21832","article-title":"Beneficial effects of nitric oxide breathing in adult patients with sickle cell crisis.","volume":"85","author":"Head","year":"2010","journal-title":"Am J Hematol"},{"issue":"3","key":"2019111809163294100_B16","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1097\/00000542-200609000-00028","article-title":"Inhaled nitric oxide for treatment of sickle cell stroke.","volume":"105","author":"Montero-Huerta","year":"2006","journal-title":"Anesthesiology"},{"issue":"1","key":"2019111809163294100_B17","doi-asserted-by":"crossref","first-page":"H39","DOI":"10.1152\/ajpheart.00162.2008","article-title":"Arginine therapy of transgenic-knockout sickle mice improves microvascular function by reducing non-nitric oxide vasodilators, hemolysis, and oxidative stress.","volume":"295","author":"Kaul","year":"2008","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"3","key":"2019111809163294100_B18","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1182\/blood-2002-07-2135","article-title":"Inhaled nitric oxide protects transgenic SAD mice from sickle cell disease-specific lung injury induced by hypoxia\/reoxygenation.","volume":"102","author":"de Franceschi","year":"2003","journal-title":"Blood"},{"issue":"6","key":"2019111809163294100_B19","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1097\/00000542-200106000-00028","article-title":"Inhaled nitric oxide improves survival rates during hypoxia in a sickle cell (SAD) mouse model.","volume":"94","author":"Martinez-Ruiz","year":"2001","journal-title":"Anesthesiology"},{"issue":"20","key":"2019111809163294100_B20","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJM199505183322001","article-title":"Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia: investigators of the multicenter study of hydroxyurea in sickle cell anemia.","volume":"332","author":"Charache","year":"1995","journal-title":"N Engl J Med"},{"key":"2019111809163294100_B21","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1182\/asheducation.V2000.1.2.20000002","article-title":"New views of sickle cell disease pathophysiology and treatment.","volume":"2000","author":"Rosse","year":"2000","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"3","key":"2019111809163294100_B22","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1097\/MOH.0b013e32834521dd","article-title":"Hydroxyurea for sickle cell anemia: what have we learned and what questions still remain?","volume":"18","author":"McGann","year":"2011","journal-title":"Curr Opin Hematol"},{"issue":"6","key":"2019111809163294100_B23","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.freeradbiomed.2004.02.073","article-title":"Nitric oxide production from hydroxyurea.","volume":"37","author":"King","year":"2004","journal-title":"Free Radical Biol Med"},{"issue":"2","key":"2019111809163294100_B24","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1172\/JCI200316672","article-title":"Hydroxyurea induces fetal hemoglobin by the nitric oxide-dependent activation of soluble guanylyl cyclase.","volume":"111","author":"Cokic","year":"2003","journal-title":"J Clin Invest"},{"issue":"3","key":"2019111809163294100_B25","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1124\/pr.58.3.5","article-title":"Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use.","volume":"58","author":"Bender","year":"2006","journal-title":"Pharmacol Rev"},{"issue":"4","key":"2019111809163294100_B26","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1073\/pnas.98.4.1847","article-title":"Mechanism for fetal globin gene expression: role of the soluble guanylate cyclase-cGMP-dependent protein kinase pathway.","volume":"98","author":"Ikuta","year":"2001","journal-title":"Proc Nat Acad Sci U S A"},{"issue":"4","key":"2019111809163294100_B27","doi-asserted-by":"crossref","first-page":"605","DOI":"10.3324\/haematol.12119","article-title":"Increased adhesive properties of neutrophils in sickle cell disease may be reversed by pharmacological nitric oxide donation.","volume":"93","author":"Canalli","year":"2008","journal-title":"Haematologica"},{"issue":"5","key":"2019111809163294100_B28","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1111\/j.1365-2141.2008.07264.x","article-title":"High expression of the cGMP-specific phosphodiesterase, PDE9A, in sickle cell disease (SCD) and the effects of its inhibition in erythroid cells and SCD neutrophils.","volume":"142","author":"Almeida","year":"2008","journal-title":"Br J Haematol"},{"issue":"7","key":"2019111809163294100_B29","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1007\/s00011-011-0315-8","article-title":"Inhibition of phosphodiesterase 9A (PDE9A) reduces cytokine-stimulated in vitro adhesion of neutrophils from sickle cell anemia individuals.","volume":"60","author":"Miguel","year":"2011","journal-title":"Inflamm Res"},{"issue":"5339","key":"2019111809163294100_B30","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.278.5339.876","article-title":"Transgenic knockout mice with exclusively human sickle hemoglobin and sickle cell disease.","volume":"278","author":"P\u00e1szty","year":"1997","journal-title":"Science"},{"issue":"4","key":"2019111809163294100_B31","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1172\/JCI45336","article-title":"CXCL1 and its receptor, CXCR2, mediate murine sickle cell vaso-occlusion during hemolytic transfusion reactions.","volume":"121","author":"Jang","year":"2011","journal-title":"J Clin Invest"},{"issue":"6","key":"2019111809163294100_B32","doi-asserted-by":"crossref","first-page":"H2715","DOI":"10.1152\/ajpheart.00986.2004","article-title":"Critical role of endothelial cell activation in hypoxia-induced vasoocclusion in transgenic sickle mice.","volume":"288","author":"Belcher","year":"2005","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"3","key":"2019111809163294100_B33","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1172\/JCI9225","article-title":"Hypoxia\/reoxygenation causes inflammatory response in transgenic sickle mice but not in normal mice.","volume":"106","author":"Kaul","year":"2000","journal-title":"J Clin Invest"},{"issue":"2","key":"2019111809163294100_B34","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1189\/jlb.0708445","article-title":"Altered levels of cytokines and inflammatory mediators in plasma and leukocytes of sickle cell anemia patients and effects of hydroxyurea therapy.","volume":"85","author":"Lanaro","year":"2009","journal-title":"J Leukoc Biol"},{"issue":"9","key":"2019111809163294100_B35","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.3324\/haematol.2010.023325","article-title":"Hydroxyurea therapy requires HbF induction for clinical benefit in a sickle cell mouse model.","volume":"95","author":"Lebensburger","year":"2010","journal-title":"Haematologica"},{"issue":"1","key":"2019111809163294100_B36","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1182\/blood-2005-11-4454","article-title":"Hydroxyurea induces the eNOS-cGMP pathway in endothelial cells.","volume":"108","author":"Cokic","year":"2006","journal-title":"Blood"},{"issue":"9","key":"2019111809163294100_B37","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1002\/ajh.21475","article-title":"Vasculopathy in sickle cell disease: Biology, pathophysiology, genetics, translational medicine, and new research directions.","volume":"84","author":"Kato","year":"2009","journal-title":"Am J Hematol"},{"issue":"3","key":"2019111809163294100_B38","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1182\/blood-2007-05-088732","article-title":"Hydroxyurea nitrosylates and activates soluble guanylyl cyclase in human erythroid cells.","volume":"111","author":"Cokic","year":"2008","journal-title":"Blood"},{"issue":"1","key":"2019111809163294100_B39","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s10048-010-0268-z","article-title":"Hydroxyurea enhances SMN2 gene expression through nitric oxide release.","volume":"12","author":"Xu","year":"2011","journal-title":"Neurogenetics"},{"issue":"5","key":"2019111809163294100_B40","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1182\/blood.V91.5.1533","article-title":"A bioavailability and pharmacokinetic study of oral and intravenous hydroxyurea.","volume":"91","author":"Rodriguez","year":"1998","journal-title":"Blood"},{"issue":"11","key":"2019111809163294100_B41","doi-asserted-by":"crossref","first-page":"3332","DOI":"10.1111\/j.1460-9568.2007.05589.x","article-title":"Expression of the cGMP-specific phosphodiesterases 2 and 9 in normal and Alzheimer's disease human brains.","volume":"25","author":"Reyes-Irisarri","year":"2007","journal-title":"Eur J Neurosci"},{"issue":"6","key":"2019111809163294100_B42","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1124\/mol.105.017608","article-title":"Characterization of the first potent and selective PDE9 inhibitor using a cGMP reporter cell line.","volume":"68","author":"Wunder","year":"2005","journal-title":"Mol Pharmacol"},{"issue":"8","key":"2019111809163294100_B43","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1182\/blood-2011-08-374447","article-title":"Hydroxyurea therapy of a murine model of sickle cell anemia inhibits the progression of pneumococcal disease by down-modulating E-selectin.","volume":"119","author":"Lebensburger","year":"2012","journal-title":"Blood"},{"issue":"10","key":"2019111809163294100_B44","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1084\/jem.20072660","article-title":"PSGL-1 engagement by E-selectin signals through Src kinase Fgr and ITAM adapters DAP12 and FcR gamma to induce slow leukocyte rolling.","volume":"205","author":"Zarbock","year":"2008","journal-title":"J Exp Med"},{"key":"2019111809163294100_B45","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1146\/annurev.immunol.25.022106.141618","article-title":"Structural basis of integrin regulation and signaling.","volume":"25","author":"Luo","year":"2007","journal-title":"Annu Rev Immunol"},{"issue":"3","key":"2019111809163294100_B46","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1016\/j.bbrc.2006.07.179","article-title":"Down-regulation of integrin alpha M beta 2 ligand-binding function by the urokinase-type plasminogen activator receptor.","volume":"348","author":"Tang","year":"2006","journal-title":"Biochem Biophys Res Commun"},{"issue":"4","key":"2019111809163294100_B47","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1182\/blood-2010-09-306167","article-title":"Hospitalization for pain in patients with sickle cell disease treated with sildenafil for elevated TRV and low exercise capacity.","volume":"118","author":"Machado","year":"2011","journal-title":"Blood"},{"issue":"4","key":"2019111809163294100_B48","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.neuropharm.2011.05.009","article-title":"The selective phosphodiesterase 9 (PDE9) inhibitor PF-04447943 (6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one) enhances synaptic plasticity and cognitive function in rodents.","volume":"61","author":"Hutson","year":"2011","journal-title":"Neuropharmacology"},{"issue":"5-6","key":"2019111809163294100_B49","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1016\/j.neuropharm.2011.12.021","article-title":"Inhibition of acetylcholinesterase and phosphodiesterase-9A has differential effects on hippocampal early and late LTP.","volume":"62","author":"Kroker","year":"2012","journal-title":"Neuropharmacology"},{"issue":"2","key":"2019111809163294100_B50","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1046\/j.1365-2141.2002.03274.x","article-title":"Nitric oxide donor properties of hydroxyurea in patients with sickle cell disease.","volume":"116","author":"Gladwin","year":"2002","journal-title":"Br J Haematol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/120\/14\/2879\/1357145\/zh804012002879.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/120\/14\/2879\/1357145\/zh804012002879.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T15:20:49Z","timestamp":1574090449000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/120\/14\/2879\/30514\/Hydroxyurea-and-a-cGMPamplifying-agent-have"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10,4]]},"references-count":50,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2012,10,4]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2012-02-409524","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,10,4]]}}}